Cargando…

Detection of HCV-Specific IFN-γ Responses in HCV Antibody and HCV RNA Negative Injecting Drug Users

BACKGROUND: Detectable HCV-specific cellular immune responses in HCV antibody and RNA negative people who inject drugs (PWID) raise the question of whether some are resistant to HCV infection. Immune responses from people who have been exposed to hepatitis C virus (HCV) and remain anti-HCV negative...

Descripción completa

Detalles Bibliográficos
Autores principales: Flynn, Jacqueline K, Sacks-Davis, Rachel, Higgs, Peter, Aitken, Campbell, Moneer, Sarah, Suppiah, Vijay, Tracy, Lilly, Ffrench, Rosemary, Bowden, Scott, Drummer, Heidi, George, Jacob, Bharadwaj, Mandvi, Hellard, Margaret
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kowsar 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909641/
https://www.ncbi.nlm.nih.gov/pubmed/24497881
http://dx.doi.org/10.5812/hepatmon.14678
_version_ 1782301877894905856
author Flynn, Jacqueline K
Sacks-Davis, Rachel
Higgs, Peter
Aitken, Campbell
Moneer, Sarah
Suppiah, Vijay
Tracy, Lilly
Ffrench, Rosemary
Bowden, Scott
Drummer, Heidi
George, Jacob
Bharadwaj, Mandvi
Hellard, Margaret
author_facet Flynn, Jacqueline K
Sacks-Davis, Rachel
Higgs, Peter
Aitken, Campbell
Moneer, Sarah
Suppiah, Vijay
Tracy, Lilly
Ffrench, Rosemary
Bowden, Scott
Drummer, Heidi
George, Jacob
Bharadwaj, Mandvi
Hellard, Margaret
author_sort Flynn, Jacqueline K
collection PubMed
description BACKGROUND: Detectable HCV-specific cellular immune responses in HCV antibody and RNA negative people who inject drugs (PWID) raise the question of whether some are resistant to HCV infection. Immune responses from people who have been exposed to hepatitis C virus (HCV) and remain anti-HCV negative are of interest for HCV vaccine development; however, limited research addresses this area. OBJECTIVES: In a cohort of HCV antibody and RNA negative PWID, we assessed whether the presence of HCV-specific IFN-γ responses or genetic associations provide any evidence of protection from HCV infection. PATIENTS AND METHODS: One hundred and ninety-eight participants were examined longitudinally for clinical, behavioral, social, environmental and genetic characteristics (IFNL3 genotype [formally IL-28B] and HLA type). Sixty-one of the 198 participants were HCV antibody and RNA negative, with 53 able to be examined longitudinally for HCV-specific IFN-γ ELISpot T cell responses. RESULTS: Ten of the 53 HCV antibody and RNA negative participants had detectable HCV-specific IFN-γ responses at baseline (18%). The magnitude of IFN-γ responses averaged 131 +/- 96 SFC/106 PBMC and the breadth was mean 1 +/- 1 pool positive. The specificity of responses were mainly directed to E2, NS4b and NS5b. Participants with (10) and without (43) HCV-specific IFN-γ responses did not differ in behavioral, clinical or genetic characteristics (P > 0.05). There was a larger proportion sharing needles (with 70%, without 49%, P = 0.320) and a higher incidence of HCV (with 35.1 per 100 py, 95% CI 14.6, 84.4, without 16.0 per 100 py, 95% CI 7.2, 35.6, P = 0.212) in those with IFN-γ responses, although not statistically significant. Half the participants with baseline IFN-γ responses became HCV RNA positive (5/10), with one of these participants spontaneously clearing HCV. The spontaneous clearer had high magnitude and broad Th1 responses, favorable IFNL3 genotype and favorable HLA types. CONCLUSIONS: This study demonstrated the detection of HCV-specific IFN-γ responses in HCV antibody and RNA negative individuals, with a tendency for HCV-specific IFN-γ responses to be associated with HCV exposure. The potential role of HCV-specific IFN-γ responses in those who remained HCV RNA negative is of value for the development of novel HCV therapeutics.
format Online
Article
Text
id pubmed-3909641
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Kowsar
record_format MEDLINE/PubMed
spelling pubmed-39096412014-02-04 Detection of HCV-Specific IFN-γ Responses in HCV Antibody and HCV RNA Negative Injecting Drug Users Flynn, Jacqueline K Sacks-Davis, Rachel Higgs, Peter Aitken, Campbell Moneer, Sarah Suppiah, Vijay Tracy, Lilly Ffrench, Rosemary Bowden, Scott Drummer, Heidi George, Jacob Bharadwaj, Mandvi Hellard, Margaret Hepat Mon Research Article BACKGROUND: Detectable HCV-specific cellular immune responses in HCV antibody and RNA negative people who inject drugs (PWID) raise the question of whether some are resistant to HCV infection. Immune responses from people who have been exposed to hepatitis C virus (HCV) and remain anti-HCV negative are of interest for HCV vaccine development; however, limited research addresses this area. OBJECTIVES: In a cohort of HCV antibody and RNA negative PWID, we assessed whether the presence of HCV-specific IFN-γ responses or genetic associations provide any evidence of protection from HCV infection. PATIENTS AND METHODS: One hundred and ninety-eight participants were examined longitudinally for clinical, behavioral, social, environmental and genetic characteristics (IFNL3 genotype [formally IL-28B] and HLA type). Sixty-one of the 198 participants were HCV antibody and RNA negative, with 53 able to be examined longitudinally for HCV-specific IFN-γ ELISpot T cell responses. RESULTS: Ten of the 53 HCV antibody and RNA negative participants had detectable HCV-specific IFN-γ responses at baseline (18%). The magnitude of IFN-γ responses averaged 131 +/- 96 SFC/106 PBMC and the breadth was mean 1 +/- 1 pool positive. The specificity of responses were mainly directed to E2, NS4b and NS5b. Participants with (10) and without (43) HCV-specific IFN-γ responses did not differ in behavioral, clinical or genetic characteristics (P > 0.05). There was a larger proportion sharing needles (with 70%, without 49%, P = 0.320) and a higher incidence of HCV (with 35.1 per 100 py, 95% CI 14.6, 84.4, without 16.0 per 100 py, 95% CI 7.2, 35.6, P = 0.212) in those with IFN-γ responses, although not statistically significant. Half the participants with baseline IFN-γ responses became HCV RNA positive (5/10), with one of these participants spontaneously clearing HCV. The spontaneous clearer had high magnitude and broad Th1 responses, favorable IFNL3 genotype and favorable HLA types. CONCLUSIONS: This study demonstrated the detection of HCV-specific IFN-γ responses in HCV antibody and RNA negative individuals, with a tendency for HCV-specific IFN-γ responses to be associated with HCV exposure. The potential role of HCV-specific IFN-γ responses in those who remained HCV RNA negative is of value for the development of novel HCV therapeutics. Kowsar 2014-01-08 /pmc/articles/PMC3909641/ /pubmed/24497881 http://dx.doi.org/10.5812/hepatmon.14678 Text en Copyright © 2014, BRCGL. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Flynn, Jacqueline K
Sacks-Davis, Rachel
Higgs, Peter
Aitken, Campbell
Moneer, Sarah
Suppiah, Vijay
Tracy, Lilly
Ffrench, Rosemary
Bowden, Scott
Drummer, Heidi
George, Jacob
Bharadwaj, Mandvi
Hellard, Margaret
Detection of HCV-Specific IFN-γ Responses in HCV Antibody and HCV RNA Negative Injecting Drug Users
title Detection of HCV-Specific IFN-γ Responses in HCV Antibody and HCV RNA Negative Injecting Drug Users
title_full Detection of HCV-Specific IFN-γ Responses in HCV Antibody and HCV RNA Negative Injecting Drug Users
title_fullStr Detection of HCV-Specific IFN-γ Responses in HCV Antibody and HCV RNA Negative Injecting Drug Users
title_full_unstemmed Detection of HCV-Specific IFN-γ Responses in HCV Antibody and HCV RNA Negative Injecting Drug Users
title_short Detection of HCV-Specific IFN-γ Responses in HCV Antibody and HCV RNA Negative Injecting Drug Users
title_sort detection of hcv-specific ifn-γ responses in hcv antibody and hcv rna negative injecting drug users
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909641/
https://www.ncbi.nlm.nih.gov/pubmed/24497881
http://dx.doi.org/10.5812/hepatmon.14678
work_keys_str_mv AT flynnjacquelinek detectionofhcvspecificifngresponsesinhcvantibodyandhcvrnanegativeinjectingdrugusers
AT sacksdavisrachel detectionofhcvspecificifngresponsesinhcvantibodyandhcvrnanegativeinjectingdrugusers
AT higgspeter detectionofhcvspecificifngresponsesinhcvantibodyandhcvrnanegativeinjectingdrugusers
AT aitkencampbell detectionofhcvspecificifngresponsesinhcvantibodyandhcvrnanegativeinjectingdrugusers
AT moneersarah detectionofhcvspecificifngresponsesinhcvantibodyandhcvrnanegativeinjectingdrugusers
AT suppiahvijay detectionofhcvspecificifngresponsesinhcvantibodyandhcvrnanegativeinjectingdrugusers
AT tracylilly detectionofhcvspecificifngresponsesinhcvantibodyandhcvrnanegativeinjectingdrugusers
AT ffrenchrosemary detectionofhcvspecificifngresponsesinhcvantibodyandhcvrnanegativeinjectingdrugusers
AT bowdenscott detectionofhcvspecificifngresponsesinhcvantibodyandhcvrnanegativeinjectingdrugusers
AT drummerheidi detectionofhcvspecificifngresponsesinhcvantibodyandhcvrnanegativeinjectingdrugusers
AT georgejacob detectionofhcvspecificifngresponsesinhcvantibodyandhcvrnanegativeinjectingdrugusers
AT bharadwajmandvi detectionofhcvspecificifngresponsesinhcvantibodyandhcvrnanegativeinjectingdrugusers
AT hellardmargaret detectionofhcvspecificifngresponsesinhcvantibodyandhcvrnanegativeinjectingdrugusers